Does the media favor ADMA or DSGN?

In the previous week, ADMA Biologics had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 6 mentions for ADMA Biologics and 3 mentions for Design Therapeutics. ADMA Biologics' average media sentiment score of 0.50 beat Design Therapeutics' score of 0.21 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DSGN or ZLAB?

In the previous week, Zai Lab had 9 more articles in the media than Design Therapeutics. MarketBeat recorded 12 mentions for Zai Lab and 3 mentions for Design Therapeutics. Zai Lab's average media sentiment score of 0.34 beat Design Therapeutics' score of 0.21 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zai Lab 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NAMS or DSGN?

In the previous week, NewAmsterdam Pharma had 13 more articles in the media than Design Therapeutics. MarketBeat recorded 16 mentions for NewAmsterdam Pharma and 3 mentions for Design Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.28 beat Design Therapeutics' score of 0.21 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, BHVN or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$3.86 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is BHVN or DSGN more profitable?

Design Therapeutics' return on equity of -35.51% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -2,271.88% -139.84% Design Therapeutics N/A -35.51% -33.35%

Does the media favor BHVN or DSGN?

In the previous week, Biohaven had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.21 beat Biohaven's score of -0.09 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CLDX or DSGN more profitable?

Design Therapeutics' return on equity of -35.51% beat Celldex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Celldex Therapeutics N/A -52.66% -47.58% Design Therapeutics N/A -35.51% -33.35%

Does the media favor CLDX or DSGN?

In the previous week, Celldex Therapeutics had 14 more articles in the media than Design Therapeutics. MarketBeat recorded 17 mentions for Celldex Therapeutics and 3 mentions for Design Therapeutics. Celldex Therapeutics' average media sentiment score of 0.93 beat Design Therapeutics' score of 0.21 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Design Therapeutics (DSGN) Competitors

$10.43 -0.15 (-1.46%)

As of 02:02 PM Eastern

Compare

DSGN vs. ADMA, ZLAB, NAMS, BHVN, and CLDX

Should you buy Design Therapeutics stock or one of its competitors? Design Therapeutics's main competitors and comparable companies include ADMA Biologics (ADMA), Zai Lab (ZLAB), NewAmsterdam Pharma (NAMS), Biohaven (BHVN), and Celldex Therapeutics (CLDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Design Therapeutics compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

ADMA Biologics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	5.81	$146.93M	$0.77	17.19
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

ADMA Biologics presently has a consensus price target of $17.50, indicating a potential upside of 32.18%. Design Therapeutics has a consensus price target of $18.57, indicating a potential upside of 75.53%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Design Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, ADMA Biologics had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 6 mentions for ADMA Biologics and 3 mentions for Design Therapeutics. ADMA Biologics' average media sentiment score of 0.50 beat Design Therapeutics' score of 0.21 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ADMA Biologics has a net margin of 35.14% compared to Design Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 42.56% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	35.14%	42.56%	26.96%
Design Therapeutics	N/A	-35.51%	-33.35%

Summary

ADMA Biologics beats Design Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to Zai Lab?

Design Therapeutics (NASDAQ:DSGN) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Design Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -44.91%. Zai Lab's return on equity of -31.15% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-35.51%	-33.35%
Zai Lab	-44.91%	-31.15%	-18.17%

Design Therapeutics currently has a consensus target price of $18.57, indicating a potential upside of 75.53%. Zai Lab has a consensus target price of $37.25, indicating a potential upside of 43.05%. Given Design Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Design Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Design Therapeutics has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Design Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Zai Lab	$460.16M	7.08	-$175.54M	-$1.79	N/A

In the previous week, Zai Lab had 9 more articles in the media than Design Therapeutics. MarketBeat recorded 12 mentions for Zai Lab and 3 mentions for Design Therapeutics. Zai Lab's average media sentiment score of 0.34 beat Design Therapeutics' score of 0.21 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zai Lab	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Design Therapeutics beats Zai Lab on 9 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Design Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	106.10	-$203.82M	-$1.69	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, NewAmsterdam Pharma had 13 more articles in the media than Design Therapeutics. MarketBeat recorded 16 mentions for NewAmsterdam Pharma and 3 mentions for Design Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.28 beat Design Therapeutics' score of 0.21 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NewAmsterdam Pharma has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

NewAmsterdam Pharma presently has a consensus price target of $49.82, indicating a potential upside of 149.47%. Design Therapeutics has a consensus price target of $18.57, indicating a potential upside of 75.53%. Given NewAmsterdam Pharma's higher possible upside, equities research analysts clearly believe NewAmsterdam Pharma is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Design Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -789.95%. NewAmsterdam Pharma's return on equity of -31.39% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-789.95%	-31.39%	-28.32%
Design Therapeutics	N/A	-35.51%	-33.35%

Summary

NewAmsterdam Pharma beats Design Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Biohaven?

Biohaven (NYSE:BHVN) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Design Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$3.86	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Biohaven has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market.

Biohaven presently has a consensus target price of $20.80, suggesting a potential upside of 48.03%. Design Therapeutics has a consensus target price of $18.57, suggesting a potential upside of 75.53%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Design Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.63
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Design Therapeutics' return on equity of -35.51% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-2,271.88%	-139.84%
Design Therapeutics	N/A	-35.51%	-33.35%

In the previous week, Biohaven had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.21 beat Biohaven's score of -0.09 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Design Therapeutics beats Biohaven on 9 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

56.6% of Design Therapeutics shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Design Therapeutics' return on equity of -35.51% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.66%	-47.58%
Design Therapeutics	N/A	-35.51%	-33.35%

Design Therapeutics has lower revenue, but higher earnings than Celldex Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,455.40	-$258.76M	-$4.30	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Celldex Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market.

In the previous week, Celldex Therapeutics had 14 more articles in the media than Design Therapeutics. MarketBeat recorded 17 mentions for Celldex Therapeutics and 3 mentions for Design Therapeutics. Celldex Therapeutics' average media sentiment score of 0.93 beat Design Therapeutics' score of 0.21 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celldex Therapeutics currently has a consensus price target of $64.08, suggesting a potential upside of 124.62%. Design Therapeutics has a consensus price target of $18.57, suggesting a potential upside of 75.53%. Given Celldex Therapeutics' higher possible upside, research analysts plainly believe Celldex Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Design Therapeutics beats Celldex Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DSGN vs. The Competition

Export

Metric	Design Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$668.26M	$4.10B	$7.86B	$12.08B
Dividend Yield	N/A	3.62%	2.46%	4.50%
P/E Ratio	-8.70	24.60	34.54	30.45
Price / Sales	N/A	16.92	8.91	5.88
Price / Cash	N/A	26.89	22.23	22.80
Price / Book	3.30	4.13	4.40	3.79
Net Income	-$69.79M	-$22.78M	$3.51B	$390.67M
7 Day Performance	2.12%	-2.60%	-1.43%	-0.37%
1 Month Performance	6.61%	-5.61%	-3.86%	-6.68%
1 Year Performance	47.68%	-0.25%	0.93%	-5.87%

Design Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DSGN Design Therapeutics	2.559 of 5 stars	$10.43 -1.5%	$18.57 +78.1%	+39.0%	$668.26M	N/A	N/A	60
ADMA ADMA Biologics	3.7487 of 5 stars	$11.11 +0.5%	$18.67 +68.0%	-19.6%	$2.48B	$510.17M	15.58	647
ZLAB Zai Lab	3.2592 of 5 stars	$21.96 +1.3%	$37.25 +69.6%	+19.0%	$2.47B	$460.16M	N/A	1,784	High Trading Volume
NAMS NewAmsterdam Pharma	3.4382 of 5 stars	$19.90 +1.7%	$48.90 +145.7%	-47.8%	$2.34B	$22.50M	N/A	100	Analyst Forecast Analyst Revision
BHVN Biohaven	3.7143 of 5 stars	$15.62 +3.0%	$20.06 +28.4%	+77.1%	$2.29B	N/A	N/A	274

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Design Therapeutics (DSGN) Competitors

DSGN vs. ADMA, ZLAB, NAMS, BHVN, and CLDX

How does Design Therapeutics compare to ADMA Biologics?

Summary

How does Design Therapeutics compare to Zai Lab?

Summary

How does Design Therapeutics compare to NewAmsterdam Pharma?

Summary

How does Design Therapeutics compare to Biohaven?

Summary

How does Design Therapeutics compare to Celldex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Design Therapeutics (DSGN) Competitors

DSGN vs. ADMA, ZLAB, NAMS, BHVN, and CLDX

How does Design Therapeutics compare to ADMA Biologics?

Which has more risk and volatility, ADMA or DSGN?

Which has preferable earnings & valuation, ADMA or DSGN?

Do analysts rate ADMA or DSGN?

Does the media favor ADMA or DSGN?

Do insiders & institutionals have more ownership in ADMA or DSGN?

Is ADMA or DSGN more profitable?

Summary

How does Design Therapeutics compare to Zai Lab?

Is DSGN or ZLAB more profitable?

Do analysts prefer DSGN or ZLAB?

Do institutionals and insiders have more ownership in DSGN or ZLAB?

Which has more volatility & risk, DSGN or ZLAB?

Which has preferable valuation and earnings, DSGN or ZLAB?

Does the media favor DSGN or ZLAB?

Summary

How does Design Therapeutics compare to NewAmsterdam Pharma?

Which has stronger earnings & valuation, NAMS or DSGN?

Does the media favor NAMS or DSGN?

Which has more volatility and risk, NAMS or DSGN?

Do analysts prefer NAMS or DSGN?

Do institutionals & insiders have more ownership in NAMS or DSGN?

Is NAMS or DSGN more profitable?

Summary

How does Design Therapeutics compare to Biohaven?

Which has preferable earnings and valuation, BHVN or DSGN?

Which has more volatility & risk, BHVN or DSGN?

Do analysts recommend BHVN or DSGN?

Is BHVN or DSGN more profitable?

Does the media favor BHVN or DSGN?

Do institutionals & insiders hold more shares of BHVN or DSGN?

Summary

How does Design Therapeutics compare to Celldex Therapeutics?

Do institutionals and insiders hold more shares of CLDX or DSGN?

Is CLDX or DSGN more profitable?

Which has stronger valuation and earnings, CLDX or DSGN?

Which has more volatility and risk, CLDX or DSGN?

Does the media favor CLDX or DSGN?

Do analysts recommend CLDX or DSGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools